Patient recruitment to the clinical study on STEEN Solution™ is now complete

Patient recruitment to the clinical study on STEEN Solution™ is now complete

A total of 22 patients have been recruited to the study, which has been designed
in consultation with the FDA, (the US Food and Drug Administration). The results
of the study will be reported within a few months.

22 patients have been included in the clinical study, which started during the
autumn of 2008. Lungs from further patients have been evaluated using the STEEN
Solution™ method, but have been assessed as not being sufficiently good to be
transplanted.

The STEEN Solution™ method considerably increases the number of potential organs
that can be transplanted. Today less than 20 percent of the lungs donated in the
USA are transplanted, due to uncertainty about the functioning of the organ. In
the long term the STEEN Solution™ method can lead to five to ten times more lung
transplantations being performed, as the demand for donated organs using today's
methods considerably exceeds the supply.

STEEN Solution™ is approved for sales in Europe, i.e. it is CE marked. The
recently completed clinical study in Canada will be part of an application for
sales approval in the USA and Canada.




February 8, 2010
Gothenburg

Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 160 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy, United
Kingdom and Japan. Production facilities are housed in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.